

1 Barry G. Felder (No. 175658)  
2 THELEN REID BROWN RAYSMAN & STEINER LLP  
3 875 Third Avenue  
4 New York, New York 10022  
5 Telephone: (212) 603-2000  
6 Facsimile: (212) 603-2001

7 Alexandra Epand (No. 191733)  
8 THELEN REID BROWN RAYSMAN & STEINER LLP  
9 333 South Hope Street, Suite 2900  
10 Los Angeles, California 90071-3048  
11 Telephone: (213) 576-8000  
12 Facsimile: (213) 576-8080

13 Attorneys for Defendants ARGYLL BIOTECHNOLOGIES, LLC,  
14 DOUGLAS McCLAIN, JR. and JAMES T. MICELI

15 **UNITED STATES DISTRICT COURT**  
16 **SOUTHERN DISTRICT OF CALIFORNIA**

17 -----x  
18 DEBORAH DONOGHUE, :

19 Plaintiff, :

20 -against- :

21 Civil Action No. 08-0510 (JM) (WMC)

22 IMMUNOSYN CORPORATION, ARGYLL  
23 BIOTECHNOLOGY LLC, DOUGLAS  
24 MCCLAIN, JR. AND JAMES T. MICELI,

25 **DECLARATION OF**  
26 **BARRY G. FELDER**

27 Defendants. :

28 -----x

19 BARRY G. FELDER declares as follows:

20 1. I am a member of Thelen Reid Brown Raysman & Steiner LLP, counsel for  
21 defendants Argyll Biotechnologies, LLC (incorrectly named as "Argyll Biotechnology LLC"),  
22 James T. Miceli and Douglas McClain, Jr. I submit this declaration in support of defendants'  
23 motion to dismiss, or, in the alternative, to transfer or stay, the action and to place certain  
24 documents before the Court.

25 2. This action (the "Third-Filed California Action"), filed March 19, 2008, seeks  
26 recovery of alleged short-swing profits from the defendants pursuant to Section 16(b) of the  
27 Securities Exchange Act. A true and correct copy of the Complaint in the Third-Filed California  
28 Action is annexed hereto as Exhibit 1.

1       3. Plaintiff in this action (“Donoghue”), who is suing derivatively on behalf of  
2 nominal defendant Immunosyn Corporation (“Immunosyn”), filed the same complaint against the  
3 same defendants in the Southern District of New York on March 11, 2008, in an action captioned  
4 *Donoghue v. Immunosyn Corp.*, Case No. 08-02434 (the “Second-Filed New York Action”). As  
5 noted below, Donoghue has now voluntarily dismissed the Second-Filed New York Action. A  
6 true and correct copy of the Complaint in the Second-Filed New York Action is annexed hereto as  
7 Exhibit 2.

8       4. Approximately three months prior to the filing of Donoghue’s actions, on  
9 December 19, 2007, another Immunosyn shareholder filed a substantially similar action against  
10 Defendants and three other parties – Argyll Equities, LLC, Cuxhaven Holdings, Ltd., and  
11 Clairsvelle Holdings, Ltd. – in the Southern District of New York, captioned *Segen v. Argyll*  
12 *Biotechnologies, LLC*, Case No. 07-11395 (the “First-Filed New York Action”). In response to a  
13 motion by defendants to dismiss the claims with respect to Cuxhaven Holdings, Ltd. and  
14 Clairsvelle Holdings, Ltd., counsel for plaintiff in the First-Filed New York Action has indicated  
15 that he intends to withdraw or limit those claims. In addition, all three parties are mentioned in  
16 both of Donoghue’s later complaints, although they are not named as defendants in those actions.  
17 A true and correct copy of the Complaint in the First-Filed New York Action is annexed hereto as  
18 Exhibit 3.

19       5. In all three actions, plaintiffs alleged short-swing profits based on alleged sales and  
20 purchases of Immunosyn shares by the defendants within a six-month period. Both plaintiffs have  
21 alleged substantially the same sale transactions, and, more importantly, have alleged that the same  
22 four transactions, occurring on June 21, 2007, August 23, 2007, and August 24, 2007 constitute  
23 “purchases” under Section 16(b), purportedly subjecting the defendants to short-swing liability.  
24 As is evident from the affirmative defenses asserted in defendants’ answers in both the First-Filed  
25 New York Action and this action, the central dispute in these actions will concern whether the four  
26 alleged “purchases” constitute purchases for purposes of Section 16(b) and, if so, whether those  
27 alleged purchases occurred within the six-month short-swing liability time frame. A true and  
28 correct copy of the Answer in the First-Filed New York Action is annexed hereto as Exhibit 4.

1 For example, with respect to the August 24, 2007 transactions, defendants have asserted in their  
2 affirmative defenses that those transactions were in fact rescissions or forfeitures in connection  
3 with consulting agreements entered into between Immunosyn and two consultants in 2006, more  
4 than six months prior to any alleged sale. The documents and witnesses relevant to the claims and  
5 defenses in each of the actions are located in New York, New Jersey, Georgia and California.

6 6. In the First-Filed New York Action, defendants have filed an answer and motion  
7 for partial dismissal of the complaint and discovery has been served. In addition, on March 20,  
8 2008, the parties in the First-Filed New York Action attended a preliminary conference before the  
9 Honorable Thomas Griesa, during which the parties discussed the claims and defenses in the  
10 action in some detail with Judge Griesa.

11 7. Donoghue filed a notice of voluntary dismissal of the Second-Filed New York  
12 Action on or about April 15, 2008. In a telephone conversation with Donoghue's counsel on April  
13 21, 2008, I expressed the defendants' preference to litigate with Donoghue in the Southern District  
14 of New York, where defendants are already defending the First-Filed New York Action. Despite  
15 this clear waiver of any objection to venue in New York, Donoghue's counsel continues to  
16 maintain that the Southern District of California is the only proper venue for this action, citing  
17 unspecified "defects" in the New York venue.<sup>1</sup>

18

19 I declare under penalty of perjury that the foregoing is true and correct.

20 Executed on April 25, 2008.

21

s/ Barry G. Felder  
Barry G. Felder

22

23

24

25

26 <sup>1</sup> Donoghue's counsel also maintains that the First-Filed New York Action is "defective" because  
27 plaintiff Segeen did not wait the full 60-day statutory period after his initial demand for suit before  
28 filing the complaint. However, as with any objection to venue, defendants have waived this  
objection.

## **EXHIBIT 1**

1 DAVID LOPEZ, ESQ. DL6779  
2 Attorney for Plaintiff (*Pro Hac Vice Applicant*)  
3 171 Edge of Woods Road  
4 P.O. Box 323  
5 Southampton, New York 11969-0323  
6 Tel: 631.287.5520  
7 Fax: 631.283.4735  
8 e-Mail: DavidLopezEsq@aol.com

ORIGINAL  
08 MAR 19 PM 3:09

CLERK, U.S. DISTRICT COURT  
SOUTHERN DISTRICT OF CALIFORNIA

44: 61 DEPUTY

7 WILLIAM R. FUHRMAN, ESQ. 58751  
8 Attorney for Plaintiff  
9 539 Encinitas Boulevard, Suite 111  
10 Encinitas, California 92024-3748  
11 San Diego, California 92024-4548  
12 Tel: 760.479.2525  
13 Fax: 801.760.4548  
14 e-Mail: Bill@SDiegolaw

12 UNITED STATES DISTRICT COURT  
13 SOUTHERN DISTRICT OF CALIFORNIA

15 DEBORAH DONOGHUE, )

16 ) '08 CV 0510 JM WMC

17 Plaintiff, )

18 - against - )

19 IMMUNOSYN CORPORATION, )

20 ARYLL BIOTECHNOLOGY LLC, ) COMPLAINT FOR RECOVERY OF  
21 DOUGLAS McCALIN, JR. and ) OF SHORT-SWING PROFITS BY  
22 JAMES T. MICELI, ) SHAREHOLDER

23 Defendants. ) (Jury Trial Demanded)

24 DEBORAH DONOGHUE, by David Lopez, Esq. and William R. Fuhrman, her  
25 attorneys, complaining of the defendants, respectfully alleges the following upon  
26  
27  
28

1 information and belief, except as to paragraph 2, which plaintiff alleges on personal  
2 knowledge:  
3  
4

5 **JURISDICTION:**

6  
7 1. This action arises under the provisions of Section 16(b) of the Securities  
8 Exchange Act of 1934, as amended (the "Act"), 15 U.S.C. Section 78p(b), and  
9 jurisdiction is conferred upon this court by Section 27 of the Act, 15 U.S.C. Section  
10 78aa.

11 **THE PARTIES:**

12  
13 2. Plaintiff is a security owner of IMMUNOSYN CORPORATION  
14 ("IMMUNOSYN"), a Delaware Corporation with principal offices at 4225 Executive  
15 Square, Suite 260, La Jolla, California 92037.

16  
17 3. At all times relevant the common stock of IMMUNOSYN was registered under  
18 Section 12(g) of the Act and was and is traded on the over-the-counter market  
19 through market makers located within this district.

20  
21 4. This action is brought in the right and for the benefit of IMMUNOSYN which is  
22 named as a party defendant solely in order to have all necessary parties before the  
23 court.

24  
25 5. At all times relevant ARGYLL BIOTECHNOLOGIES LLC ("ARGYLL") was  
26 and is a Texas limited liability entity with principal offices at 4225 Executive Square,  
27 Suite 260, La Jolla, California 92037, the same space occupied by IMMUNOSYN.

1       6. ARGYLL was and is a beneficial owner of more than 10% of the common stock  
2 of IMMUNOSYN and thereby within the reach of Section 16(b) of the Act with  
3 respect to its trading activities in the equity securities of IMMUNOSYN.  
4

5       7. At all times relevant DOUGLAS McCLAIN, JR. ("McCLAIN") was and is the  
6 president of ARGYLL and along with JAMES T. MICELI ("MICELI") one of the  
7 two beneficial owners of its equity securities.  
8

9       8. McCLAIN has a principal place of business at 4225 Executive Square, Suite 260,  
10 La Jolla, California 92037, the same space occupied by IMMUNOSYN.  
11

12       9. At all times relevant McCLAIN was an officer and/or director of IMMUNOSYN,  
13 to wit: chairman of the board and corporate secretary. Additionally, McCLAIN is  
14 directly and through intermediate entities a beneficial owner of more than 10% of the  
15 common stock of IMMUNOSYN. McCLAIN is within the reach of Section 16(b) of  
16 the Act with respect to his trading activities in the equity securities of  
17 IMMUNOSYN.  
18

19       10. McCLAIN is the 100% owner of CLAIRSVILLE HOLDINGS, INC.  
20 (CLAIRSVILLE), a British Virgin Islands company, which is an owner, for  
21 McCLAIN's benefit, of shares of IMMUNOSYN  
22

23       11. At all times relevant MICELI was and is, both through direct ownership and  
24 through the ownership of intermediate entities which hold shares of IMMUNOSYN  
25 for his benefit, a more-than-10% beneficial owner of the common stock of  
26 IMMUNOSYN and within the reach of Section 16(b) of the Act.  
27

1 12. At all times relevant MICELI was and is the chief executive officer of ARGYLL  
2 and along with McCLAIN one of the two beneficial owners of its equity securities.  
3

4 13. MICELI has a principal place of business at 4255 Executive Square, Suite 260, La  
5 Jolla, California 92037, the same space occupied by IMMUNOSYN.  
6

7 14. MICELI is the 100% owner of CUXHAVEN HOLDINGS LTD., a British Virgin  
8 Islands company, which is an owner for MICELI's benefit of shares of  
9 IMMUNOSYN.  
10

11 15. McCLAIN and MICELI are, respectively, president and chief executive officer of  
12 ARGYLL EQUITIES ("EQUITIES"), a Texas limited liability company whose  
13 principal office is 4225 Executive Square, Suite 260, La Jolla, California 92037, the  
14 same space occupied by IMMUNOSYN.  
15

16 16. McCLAIN and MICELI are the sole shareholders of ARGYLL EQUITIES which  
17 is an owner, for McCLAIN's and MICELI's benefit, of shares of IMMUNOSYN.  
18

19 17. McCLAIN and MICELI each own 45% of PADMORE, the remaining 10% being  
20 owned by McCLAIN's father.  
21

22 18. PADMORE is an owner, for *inter alia*, McCLAIN's AND MICELI's benefit, of  
23 shares of IMMUNOSYN.  
24

25 19. By reason of McCLAIN's and MICELI's ownership interests in ARGYLL,  
26 CLAIRSVILLE, CUXHAVEN, EQUITIES and PADMORE, McCLAIN and  
27 MICELI were and are the beneficial owners of shares of IMMUNOSYN owned of  
28

1 record by those entities to the extent of their respective pecuniary interests in those  
2 entities.  
3

4 **STATUTORY REQUISITES:**

5 20. The violations of Section 16(b) of the Act to be described herein involve non-  
6 exempt securities in non-exempt transactions engaged in by non-exempt persons  
7 within the meaning of the Act.  
8

9 21. Demand for prosecution was made on IMMUNOSYN on October 26, 2007.  
10 More than 60 days have passed from the date of the initial demand with  
11 IMMUNOSYN declining to discuss the matter with plaintiff's counsel. Further delay  
12 in the filing of suit would be a futile gesture, the mandatory statutory waiting period  
13 having been observed.  
14

15 22. Some or all of the transactions to be described herein were effected in whole or in  
16 part within the Southern District of California.  
17

18 23. All defendants reside, have principal places of business and are found within the  
19 Southern District of California.  
20

21 24. This action is brought within two years of the occurrence of the violations to be  
22 described herein or within two years of the time, if ever, when reports required by 15  
23 U.S.C. 78p(a) setting forth the substance of the transactions here complained of were  
24 first filed with the Securities & Exchange Commission.  
25

26  
27  
28

1 **FIRST CLAIM FOR RELIEF:**

2

3 25. McCLAIN made the following sales of IMMUNOSYN common stock on the  
 4 dates, in the quantities and at the prices here shown:

5	6 Date	7 Number of Shares	8 Price Per Share
9	10 04/26/2007	11 200,000	12 \$0.0001
13	14 04/26/2007	15 38,500	16 3.25
17	18 04/26/2007	19 83,050	20 4.55
21	22 04/26/2007	23 572,000	24 4.55
25	26 04/26/2007	27 62,000	28 4.84
29	30 04/26/2007	31 22,500	32 5.00
33	34 04/26/2007	35 18,500	36 5.00
37	38 04/26/2007	39 4,950	40 5.05
41	42 04/26/2007	43 39,050	44 9.09
45	46 06/12/2007	47 38,632.5	48 5.00
49	50 07/20/2007	51 39,500	52 0.004
53	54 07/20/2007	55 63,550	56 5.00
57	58 07/20/2007	59 2,000	60 5.00
61	62 07/20/2007	63 49,500	64 5.00
65	66 08/23/2007	67 141,120	68 5.00
69	70 08/23/2007	71 14,850	72 4.55
73	74 10/03/2007	75 187,500	76 0.667
77	78 10/03/2007	79 12,500	80 2.00
81	82 10/03/2007	83 78,450	84 5.00
85	86 10/03/2007	87 70,101	88 7.50
89	90 10/18/2007	91 12,250	92 5.00
93	94 10/18/2007	95 57,033.5	96 7.50
97	98 10/18/2007	99 124,500	100 10.00

20 26. MICELI made the following sales of IMMUNOSYN common stock on the dates,  
 21 in the quantities and at the prices here shown:

22	23 Date	24 Number of Shares	25 Price Per Share
26	27 04/26/2007	28 200,000	29 \$0.0001
30	31 04/26/2007	32 38,500	33 3.25
34	35 04/26/2007	36 83,050	37 4.55
38	39 04/26/2007	40 572,000	41 4.55
42	43 04/26/2007	44 62,000	45 4.84
47	48 04/26/2007	49 22,500	50 5.00
52	53 04/26/2007	54 18,500	55 5.00
57	58 04/26/2007	59 4,950	60 5.05
61	62 04/26/2007	63 39,050	64 9.09

1	06/12/2007	38,632.5	5.00
2	07/20/2007	39,500	0.004
3	07/20/2007	63,550	5.00
4	07/20/2007	2,000	5.00
5	07/20/2007	49,500	5.00
6	08/23/2007	192,470	4.97
7	08/24/2007	125,000	10.00
8	10/03/2007	367,069	2.98
9	10/18/2007	136,250	9.57
10	10/18/2007	193,783.5	8.95

27. ARYLL made the following sales of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown, all of which are attributable to McCLAIN and MICELI in proportion to their pecuniary interests in ARYLL:

	Date	Number of Shares	Price Per Share
12	04/26/2007	77,000	\$3.25
13	04/26/2007	166,100	4.55
14	04/26/2007	124,000	4.84
15	04/26/2007	45,000	5.00
16	07/20/2007	127,100	5.00
17	07/20/2007	4,000	5.00
18	10/03/2007	375,000	0.67
19	10/03/2007	25,000	2.00
20	10/03/2007	119,400	5.00
21	10/03/2007	140,202	7.50
22	10/18/2007	1,000	5.00
23	10/18/2007	114,067	7.50
24	10/24/2007	16,000	5.00

28. EQUITIES made the following sales of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown all of which are attributable to McCLAIN and MICELI in proportion to their pecuniary interests in EQUITIES:

	Date	Number of Shares	Price Per Share
25	04/26/2007	400,000	\$0.0001
26	04/26/2007	1,144,000	4.55
27	04/26/2007	37,000	5.00
28	04/26/2007	9,900	5.05
	04/26/2007	78,100	9.09
	07/20/2007	79,000	0.004

1	07/20/2007	99,000	5.00
2	08/23/2007	73,000	5.00
3	10/03/2007	37,500	5.00
4	10/03/2007	37,036	7.50
5	10/18/2007	23,500	5.00
6	10/18/2007	249,000	10.00

5  
6 29. PADMORE made the following sales of IMMUNOSYN common stock on the  
7 dates, in the quantities and at the prices here shown, all of which are attributable to  
8 McCLAIN and MICELI in proportion to their pecuniary interests in PADMORE:

9	Date	Number of Shares	Price Per Share
10	06/12/2007	85,850	\$5.00
11	08/23/2007	33,000	4.55
12	08/23/2007	313,600	5.00

12 30. McCLAIN made the following purchases of IMMUNOSYN common stock on  
13 the dates, in the quantities and at the prices here shown:

14	Date	Number of Shares	Price Per Share
15	06/21/2007	1,250,000	\$0.0001
16	08/23/2007	16,500	4.55
17	08/23/2007	40,000	5.00
18	08/24/2007	125,000	0.0001

18 31. MICELI made the following purchases of IMMUNOSYN common stock on the  
19 dates, in the quantities and at the prices here shown:

21	Date	Number of Shares	Price Per Share
22	06/21/2007	1,350,000	0.0001
23	08/23/2007	16,500	4.55
24	08/23/2007	40,000	5.00
25	08/24/2007	125,000	0.0001

25 32. EQUITIES made the following purchases of IMMUNOSYN common stock on  
26 the dates, in the quantities and at the prices here shown, all of which are attributable  
27 to McCLAIN and MICELI in proportion to their pecuniary interests in EQUITIES:

	Date	Number of Shares	Price Per Share
1	06/21/2007	2,700,000	\$0.001
2	08/24/2007	250,000	0.00001

3  
4 33. ARGYLL made the following purchases of IMMUNOSYN common stock on the  
5 dates, in the quantities and at the prices here shown, all of which are attributable to  
6 McCRAIN and MICELI in proportion to their pecuniary interests in ARGYLL:  
7  
8

	Date	Number of Shares	Price Per Share
9	08/23/2007	33,000	\$4.55
10	08/23/2007	80,000	5.00

11  
12 34. The foregoing purchases and sales are matchable against one another using the  
13 "lowest-in, highest out" method and produce profits recoverable from ARGYLL,  
14 McCRAIN and MICELI to the extent of their respective pecuniary interests in such  
15 profits. The amounts of such profits are unknown to Plaintiff but are estimated to  
16 exceed \$12,500,000.  
17

18  
19 35. Such profits are recoverable on behalf of IMMUNOSYN by Plaintiff as a  
20 shareholder of IMMUNOSYN, the latter, under the control of McCRAIN and  
21 MICELI, having failed or refused to act in its own right and for its own benefit.  
22

**SECOND CLAIM FOR RELIEF:**

23  
24 36. Some of the Schedules 13D and Forms 4 filed by the defendants and their  
25 intermediary entities are internally contradictory and inconsistent in their descriptions  
26 of events material to this suit. This Second Claim For Relief is a precaution against  
27 possible errors of details attributable to inaccuracies in the public record.  
28

1 37. ARGYLL, McLAIN and MICELI, acting during periods not barred by the  
2 statute of limitations measured from the date of the filing of this complaint, purchased  
3 and sold or sold and purchased equity securities or equity security equivalents of  
4 IMMUNOSYN within periods of less than six months of each other while more than  
5 10% beneficial owners and/or officers of IMMUNOSYN.  
6


7 38. By reason of such purchases and sales or sales and purchases of its equity  
8 securities or equity security equivalents within periods of less than six months of one  
9 another while insiders of IMMUNOSYN, ARGYLL, McLAIN and MICELI realized  
10 profits, the exact amounts thereof being unknown to Plaintiff, which profits inure to  
11 the benefit, and are recoverable by plaintiff on behalf, of IMMUNOSYN.  
12

13 **WHEREFORE**, Plaintiff demands judgment:  
14

15 a) Requiring ARGYLL, McLAIN and MICELI to account for and to pay over to  
16 IMMUNOSYN the short-swing profits realized and retained by them in violation of  
17 Section 16(b) of the Act, together with appropriate interest and the costs of this suit;  
18  
19 b) Awarding to Plaintiff her costs and disbursements including reasonable attorney's,  
20 accountants and expert witness fees; and  
21  
22 c) Granting to Plaintiff such other and further relief as the court may deem just and  
23 proper.  
24  
25  
26  
27  
28

1 Dated: Southampton, New York  
2 March 15, 2008

3 Yours, etc.  
4

5   
6 David Lopez, Esq.  
(*Pro Hac Vice Applicant*)

7 Dated: San Diego, California  
8 March 17, 2008

9 \_\_\_\_\_  
10 William R. Fuhrman

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**UNITED STATES  
DISTRICT COURT  
SOUTHERN DISTRICT OF CALIFORNIA  
SAN DIEGO DIVISION**

**# 148940 - SH**

**March 18, 2008  
15:09:29**

**Civ Fil Non-Pris**  
USAO #: 08CV0510  
Judge.: JEFFREY T MILLER  
Amount.: \$350.00 CK  
Check#: BC2078

**Total-> \$350.00**

**FROM: DONOGHUE V. IMMUNOSYN CORP**

JS 44 (Rev. 11/04)

## CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON THE REVERSE OF THE FORM.)

FILED

## I. (a) PLAINTIFFS

DEBORAH DONOGHUE

(b) County of Residence of First Listed Plaintiff WESTCHESTER, N.Y.  
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorney's (Firm Name, Address, and Telephone Number)

DAVID LOPEZ, ESQ., 171 EDGE OF WOODS RD., P.O. 323  
SOUTHAMPTON, NEW YORK 11968 // 631.287.5520

## II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

<input type="checkbox"/> 1 U.S. Government Plaintiff	<input checked="" type="checkbox"/> 3 Federal Question (U.S. Government Not a Party)
<input type="checkbox"/> 2 U.S. Government Defendant	<input type="checkbox"/> 4 Diversity (Indicate Citizenship of Parties in Item III)

## III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

Citizen of This State	<input type="checkbox"/> 1 <input checked="" type="checkbox"/> 2	Incorporated or Principal Place of Business In This State	<input type="checkbox"/> 4 <input checked="" type="checkbox"/> 5
Citizen of Another State	<input type="checkbox"/> 2 <input checked="" type="checkbox"/> 3	Incorporated and Principal Place of Business In Another State	<input type="checkbox"/> 5 <input checked="" type="checkbox"/> 6
Citizen or Subject of a Foreign Country	<input type="checkbox"/> 3 <input checked="" type="checkbox"/> 4	Foreign Nation	<input type="checkbox"/> 6 <input checked="" type="checkbox"/> 7

## IV. NATURE OF SUIT (Place an "X" in One Box Only)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
<input type="checkbox"/> 110 Insurance	<b>PERSONAL INJURY</b>	<b>PERSONAL INJURY</b>	<b>PROPERTY RIGHTS</b>	<input type="checkbox"/> 400 State Reapportionment
<input type="checkbox"/> 120 Marine	<input type="checkbox"/> 310 Airplane	<input type="checkbox"/> 362 Personal Injury - Med. Malpractice	<input type="checkbox"/> 422 Appeal 28 USC 158	<input type="checkbox"/> 410 Antitrust
<input type="checkbox"/> 130 Miller Act	<input type="checkbox"/> 315 Airplane Product Liability	<input type="checkbox"/> 365 Personal Injury - Product Liability	<input type="checkbox"/> 423 Withdrawal 28 USC 157	<input type="checkbox"/> 430 Banks and Banking
<input type="checkbox"/> 140 Negotiable Instrument	<input type="checkbox"/> 320 Assault, Libel & Slander	<input type="checkbox"/> 368 Asbestos Personal Injury Product Liability		<input type="checkbox"/> 450 Commerce
<input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment	<input type="checkbox"/> 330 Federal Employers' Liability	<input type="checkbox"/> 370 Other Fraud	<input type="checkbox"/> 460 Deportation	<input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations
<input type="checkbox"/> 151 Medicare Act	<input type="checkbox"/> 340 Marine	<input type="checkbox"/> 371 Truth in Lending	<input type="checkbox"/> 480 Consumer Credit	<input type="checkbox"/> 490 Cable/Sat TV
<input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excl. Veterans)	<input type="checkbox"/> 345 Marine Product Liability	<input type="checkbox"/> 380 Other Personal Property Damage	<input type="checkbox"/> 510 Selective Service	<input type="checkbox"/> 810 Securities/Commodities/ Exchange
<input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits	<input type="checkbox"/> 350 Motor Vehicle	<input type="checkbox"/> 385 Property Damage Product Liability	<input type="checkbox"/> 850 State/Local Government	<input type="checkbox"/> 875 Customer Challenge 12 USC 3410
<input type="checkbox"/> 160 Stockholders' Suits	<input type="checkbox"/> 355 Motor Vehicle Product Liability	<input type="checkbox"/> 390 Other Personal Injury		<input type="checkbox"/> 890 Other Statutory Actions
<input type="checkbox"/> 190 Other Contract	<input type="checkbox"/> 360 Other Personal Injury		<b>SOCIAL SECURITY</b>	<input type="checkbox"/> 891 Agricultural Acts
<input type="checkbox"/> 195 Contract Product Liability			<input type="checkbox"/> 861 HIA (1395I)	<input type="checkbox"/> 892 Economic Stabilization Act
<input type="checkbox"/> 196 Franchise			<input type="checkbox"/> 862 Black Lung (923)	<input type="checkbox"/> 893 Environmental Matters
	<b>REAL PROPERTY</b>	<b>CIVIL RIGHTS</b>	<input type="checkbox"/> 863 DIWC/DIWW (405(g))	<input type="checkbox"/> 894 Energy Allocation Act
<input type="checkbox"/> 210 Land Condemnation	<input type="checkbox"/> 441 Voting	<input type="checkbox"/> 510 Motions to Vacate Sentence	<input type="checkbox"/> 864 SSID Title XVI	<input type="checkbox"/> 895 Freedom of Information Act
<input type="checkbox"/> 220 Foreclosure	<input type="checkbox"/> 442 Employment	<b>Habeas Corpus:</b>	<input type="checkbox"/> 865 RSI (405(g))	<input type="checkbox"/> 900 Appeal of Fee Determination Under Equal Access to Justice
<input type="checkbox"/> 230 Rent Lease & Ejectment	<input type="checkbox"/> 443 Housing/ Accommodations	<input type="checkbox"/> 530 General		<input type="checkbox"/> 950 Constitutionality of State Statutes
<input type="checkbox"/> 240 Torts to Land	<input type="checkbox"/> 444 Welfare	<input type="checkbox"/> 535 Death Penalty		
<input type="checkbox"/> 245 Tort Product Liability	<input type="checkbox"/> 445 Amer. w/Disabilities - Employment	<input type="checkbox"/> 540 Mandamus & Other		
<input type="checkbox"/> 290 All Other Real Property	<input type="checkbox"/> 446 Amer. w/Disabilities - Other	<input type="checkbox"/> 550 Civil Rights		
	<input type="checkbox"/> 440 Other Civil Rights	<input type="checkbox"/> 555 Prison Condition		

V. ORIGIN (Place an "X" in One Box Only)

<input checked="" type="checkbox"/> 1 Original Proceeding	<input type="checkbox"/> 2 Removed from State Court	<input type="checkbox"/> 3 Remanded from Appellate Court	<input type="checkbox"/> 4 Reinstated or Reopened	<input type="checkbox"/> 5 Transferred from another district (specify) _____	<input type="checkbox"/> 6 Multidistrict Litigation	<input type="checkbox"/> 7 Appeal to District Judge from Magistrate Judgment
---	---	--	---	--	---	--

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity): 15 USC 78p(b)

Brief description of cause: SHAREHOLDER SUIT TO RECOVERY SHORT-SWING PROFITS

VII. REQUESTED IN COMPLAINT:  CHECK IF THIS IS A CLASS ACTION UNDER F.R.C.P. 23 DEMAND \$ ACCOUNT & PAY JURY DEMAND:  Yes  No

VIII. RELATED CASE(S) IF ANY (See instructions): JUDGE N/A DOCKET NUMBER \_\_\_\_\_

DATE 03/15/2008 SIGNATURE OF ATTORNEY OF RECORD David Lopez

FOR OFFICE USE ONLY

RECEIPT # 148940 AMOUNT \$350 APPLYING IFFP JUDGE MAG. JUDGE

SL 3/19/08

(R)

## **EXHIBIT 2**

1222008

AO 440 (Rev. 8/01) Summons in a Civil Action

## UNITED STATES DISTRICT COURT

SOUTHERN

District of

NEW YORK

**DEBORAH DONOGHUE,**

Plaintiff,

**SUMMONS IN A CIVIL ACTION****- against -****IMMUNOSYN CORPORATION,  
ARGYLL BIOTECHNOLOGY LLC,  
DOUGLAS McCALIN, JR. and  
JAMES T. MICELI,**

CASE NUMBER:

**08 CV 02434****Defendants.**


TO: (Name and address of Defendant)

JAMES T. MICELI  
4225 EXECUTIVE SQUARE, SUITE 260  
LA JOLLA, CALIFORNIA 92037**YOU ARE HEREBY SUMMONED** and required to serve on **PLAINTIFF'S ATTORNEY** (name and address)DAVID LOPEZ, ESQ.  
171 EDGE OF WOODS ROAD, P.O. 323  
SOUTHAMPTON, NEW YORK 11968

an answer to the complaint which is served on you with this summons, within 20 days after service of this summons on you, exclusive of the day of service. If you fail to do so, judgment by default will be taken against you for the relief demanded in the complaint. Any answer that you serve on the parties to this action must be filed with the Clerk of this Court within a reasonable period of time after service.

**J. MICHAEL McMAHON**

CLERK



MAR 11 2008

DATE

(By) DEPUTY CLERK

**JUDGE COTE**

**COPY**

DAVID LOPEZ, ESQ.  
Attorney for Plaintiff  
171 Edge of Woods Road  
P.O. Box 323  
Southampton, New York 11969-0323  
Tel: 631.287.5520  
Fax: 631.283.4735  
e-Mail: DavidLopezEsq@aol.com

08 CV 02434

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK**


**DEBORAH DONOGHUE,**

**Plaintiff,**

**- against -**

**IMMUNOSYN CORPORATION,  
ARGYLL BIOTECHNOLOGY LLC,  
DOUGLAS McCLAIN, JR. and  
JAMES T. MICELI,**

**Defendants.**



DEBORAH DONOGHUE, by David Lopez, Esq., her attorney, complaining of the defendants, respectfully alleges the following upon information and belief, except as to paragraph 2, which plaintiff alleges on personal knowledge:

**JURISDICTION:**

1. This action arises under the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act"), 15 U.S.C. Section 78p(b), and jurisdiction is conferred upon this court by Section 27 of the Act, 15 U.S.C. Section 78aa.

**COPY**

DAVID LOPEZ, ESQ.  
Attorney for Plaintiff  
171 Edge of Woods Road  
P.O. Box 323  
Southampton, New York 11969-0323  
Tel: 631.287.5520  
Fax: 631.283.4735  
e-Mail: DavidLopezEsq@aol.com

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK**

**DEBORAH DONOGHUE,**

**Plaintiff,**

**- against -**

**IMMUNOSYN CORPORATION,  
ARGYLL BIOTECHNOLOGY LLC,  
DOUGLAS McCALIN, JR. and  
JAMES T. MICELI,**

**COMPLAINT**

**Defendants.**

DEBORAH DONOGHUE, by David Lopez, Esq., her attorney, complaining of the defendants, respectfully alleges the following upon information and belief, except as to paragraph 2, which plaintiff alleges on personal knowledge:

**JURISDICTION:**

1. This action arises under the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act"), 15 U.S.C. Section 78p(b), and jurisdiction is conferred upon this court by Section 27 of the Act, 15 U.S.C. Section 78aa.

**THE PARTIES:**

2. Plaintiff is a security owner of IMMUNOSYN CORPORATION ("IMMUNOSYN"), a Delaware Corporation with principal offices at 4225 Executive Square, Suite 260, La Jolla, California 92037.

3. At all times relevant the common stock of IMMUNOSYN was registered under Section 12(g) of the Act and was and is traded on the over-the-counter market through market makers located within this district.

4. This action is brought in the right and for the benefit of IMMUNOSYN which is named as a party defendant solely in order to have all necessary parties before the court.

5. At all times relevant ARGYLL BIOTECHNOLOGIES LLC ("ARGYLL") was and is a Texas limited liability entity with principal offices at 4225 Executive Square, Suite 260, La Jolla, California 92037, the same space occupied by IMMUNOSYN.

6. ARGYLL was and is a beneficial owner of more than 10% of the common stock of IMMUNOSYN and thereby within the reach of Section 16(b) of the Act with respect to its trading activities in the equity securities of IMMUNOSYN.

7. At all times relevant DOUGLAS McCLAIN, JR. ("McCLAIN") was and is the president of ARGYLL and along with JAMES T. MICELI ("MICELI") one of the two beneficial owners of its equity securities.

8. McCRAIN has a principal place of business at 4225 Executive Square, Suite 260, La Jolla, California 92037, the same space occupied by IMMUNOSYN.

9. At all times relevant McCRAIN was an officer and/or director of IMMUNOSYN, to wit: chairman of the board and corporate secretary. Additionally, McCRAIN is directly and through intermediate entities a beneficial owner of more than 10% of the common stock of IMMUNOSYN. McCRAIN is within the reach of Section 16(b) of the Act with respect to his trading activities in the equity securities of IMMUNOSYN.

10. McCRAIN is the 100% owner of CLAIRSVILLE HOLDINGS, INC. (CLAIRSVILLE), a British Virgin Islands company, which is an owner, for McCRAIN's benefit, of shares of IMMUNOSYN

11. At all times relevant MICELI was and is, both through direct ownership and through the ownership of intermediate entities which hold shares of IMMUNOSYN for his benefit, a more-than-10% beneficial owner of the common stock of IMMUNOSYN and within the reach of Section 16(b) of the Act.

12. At all times relevant MICELI was and is the chief executive officer of ARGYLL and along with McCRAIN one of the two beneficial owners of its equity securities.

13. MICELI has a principal place of business at 4255 Executive Square, Suite 260, La Jolla, California 92037, the same space occupied by IMMUNOSYN.

14. MICELI is the 100% owner of CUXHAVEN HOLDINGS LTD., a British Virgin Islands company, which is an owner for MICELI's benefit of shares of IMMUNOSYN.

15. McCLAIN and MICELI are, respectively, president and chief executive officer of ARGYLL EQUITIES ("EQUITIES"), a Texas limited liability company whose principal office is 4225 Executive Square, Suite 260, La Jolla, California 92037, the same space occupied by IMMUNOSYN.

16. McCLAIN and MICELI are the sole shareholders of ARGYLL EQUITIES, which is an owner, for McCLAIN's and MICELI's, benefit of shares of IMMUNOSYN.

17. McCLAIN and MICELI each own 45% of PADMORE, the remaining 10% being owned by McCLAIN's father.

18. By reason of McCLAIN's and MICELI's ownership interests in ARGYLL, CLAIRSVILLE, CUXHAVEN, EQUITIES and PADMORE, McCLAIN and MICELI were and are the beneficial owners of shares of IMMUNOSYN owned of record by those entities to the extent of their respective pecuniary interests in those entities.

**STATUTORY REQUISITES:**

19. The violations of Section 16(b) of the Act to be described herein involve non-exempt securities in non-exempt transactions engaged in by non-exempt persons within the meaning of the Act.

20. Demand for prosecution was made on IMMUNOSYN on October 26, 2007. More than 60 days have passed from the date of the initial demand with IMMUNOSYN declining to discuss the matter with plaintiff's counsel. Further delay in the filing of suit would be a futile gesture, the mandatory statutory waiting period having been observed.

21. Some or all of the transactions to be described herein were effected in whole or in part within the Southern District of New York through market makers located within the district.

22. This action is brought within two years of the occurrence of the violations to be described herein or within two years of the time, if ever, when reports required by 15 U.S.C. 78p(a) setting forth the substance of the transactions here complained of were first filed with the Securities & Exchange Commission.

**FIRST CLAIM FOR RELIEF:**

23. McCLAIN made the following sales of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown:

Date	Number of Shares	Price Per Share
04/26/2007	200,000	\$0.0001
04/26/2007	38,500	3.25
04/26/2007	83,050	4.55
04/26/2007	572,000	4.55
04/26/2007	62,000	4.84
04/26/2007	22,500	5.00
04/26/2007	18,500	5.00
04.26.2007	4,950	5.05
04/26/2007	39,050	9.09
06/12/2007	38,632.5	5.00
07/20/2007	39,500	0.004
07/20/2007	63,550	5.00
07/20/2007	2,000	5.00
07/20/2007	49,500	5.00
08/23/2007	141,120	5.00
08/23/2007	14,850	4.55
10/03/2007	187,500	0.667
10/03/2007	12,500	2.00
10/03/2007	78,450	5.00
10/03/2007	70,101	7.50
10/18/2007	12,250	5.00

10/18/2007	57,033.5	7.50
10/18/2007	124,500	10.00

24. MICELI made the following sales of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown:

Date	Number of Shares	Price Per Share
04/26/2007	200,000	\$0.0001
04/26/2007	38,500	3.25
04/26/2007	83,050	4.55
04/26/2007	572,000	4.55
04/26/2007	62,000	4.84
04/26/2007	22,500	5.00
04/26/2007	18,500	5.00
04/26/2007	4,950	5.05
04/26/2007	39,050	9.09
06/12/2007	38,632.5	5.00
07/20/2007	39,500	0.004
07/20/2007	63,550	5.00
07/20/2007	2,000	5.00
07/20/2007	49,500	5.00
08/23/2007	192,470	4.97
08/24/2007	125,000	10.00
10/03/2007	367,069	2.98
10/18/2007	136,250	9.57
10/18/2007	193,783.5	8.95

25. ARGYLL made the following sales of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown, all of which are attributable to McClain and MICELI in proportion to their pecuniary interests in ARGYLL:

Date	Number of Shares	Price Per Share
04/26/2007	77,000	\$3.25
04/26/2007	166,100	4.55
04/26/2007	124,000	4.84
04/26/2007	45,000	5.00
07/20/2007	127,100	5.00
07/20/2007	4,000	5.00
10/03/2007	375,000	0.67
10/03/2007	25,000	2.00
10/03/2007	119,400	5.00
10/03/2007	140,202	7.50

10/18/2007	1,000	5.00
10/18/2007	114,067	7.50
10/24/2007	16,000	5.00

26. EQUITIES made the following sales of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown, all of which are attributable to McCLAIN and MICELI in proportion to their pecuniary interests in EQUITIES:

Date	Number of Shares	Price Per Share
04/26/2007	400,000	\$0.0001
04/26/2007	1,144,000	4.55
04/26/2007	37,000	5.00
04/26/2007	9,900	5.05
04/26/2007	78,100	9.09
07/20/2007	79,000	0.004
07/20/2007	99,000	5.00
08/23/2007	73,000	5.00
10/03/2007	37,500	5.00
10/03/2007	37,036	7.50
10/18/2007	23,500	5.00
10/18/2007	249,000	10.00

27. PADMORE made the following sales of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown, all of which are attributable to McCLAIN and MICELI in proportion to their pecuniary interests in PADMORE:

Date	Number of Shares	Price Per Share
06/12/2007	85,850	\$5.00
08/23/2007	33,000	4.55
08/23/2007	313,600	5.00

28. McCLAIN made the following purchases of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown:

Date	Number of Shares	Price Per Share
06/21/2007	1,250,000	\$0.0001
08/23/2007	16,500	4.55
08/23/2007	40,000	5.00
08/24/2007	125,000	0.0001

29. MICELI made the following purchases of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown:

<b>Date</b>	<b>Number of Shares</b>	<b>Price Per Share</b>
06/21/2007	1,350,000	0.0001
08/23/2007	16,500	4.55
08/23/2007	40,000	5.00
08/24/2007	125,000	0.0001

30. EQUITIES made the following purchases of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown, all of which are attributable to McCLAIN and MICELI in proportion to their pecuniary interests in EQUITIES:

<b>Date</b>	<b>Number of Shares</b>	<b>Price Per Share</b>
06/21/2007	2,700,000	\$0.001
08/24/2007	250,000	0.00001

31. ARGYLL made the following purchases of IMMUNOSYN common stock on the dates, in the quantities and at the prices here shown, all of which are attributable to McCLAIN and MICELI in proportion to their pecuniary interests in ARGYLL:

<b>Date</b>	<b>Number of Shares</b>	<b>Price Per Share</b>
08/23/2007	33,000	\$4.55
08/23/2007	80,000	5.00

32. The foregoing purchases and sales are matchable against one another using the "lowest-in, highest out" method and produce profits recoverable from ARGYLL, McCAIN and MICELI to the extent of their respective pecuniary interests in such profits. The amounts of such profits are unknown to Plaintiff but are estimated to exceed \$12,500,000.

33. Such profits are recoverable on behalf of IMMUNOSYN by Plaintiff as a shareholder of IMMUNOSYN, the latter, under the control of McCLAIN and MICELI, having failed or refused to act in its own right and for its own benefit.

**SECOND CLAIM FOR RELIEF:**

34. Some of the Schedules 13D and Forms 4 filed by the defendants and their intermediary entities are internally contradictory and inconsistent in their descriptions of events material to this suit. This Second Claim For Relief is a precaution against possible errors of details attributable to inaccuracies in the public record.

35. ARGYLL, McCLAIN and MICELI, acting during periods not barred by the statute of limitations measured from the date of the filing of this complaint, purchased and sold or sold and purchased equity securities or equity security equivalents of IMMUNOSYN within periods of less than six months of each other while more than 10% beneficial owners and/or officers of IMMUNOSYN.


36. By reason of such purchases and sales or sales and purchases of its equity securities or equity security equivalents within periods of less than six months of one another while insiders of IMMUNOSYN, ARGYLL, McCLAIN and MICELI realized profits, the exact amounts thereof being unknown to Plaintiff, which profits inure to the benefit, and are recoverable by plaintiff on behalf, of IMMUNOSYN.

**WHEREFORE**, Plaintiff demands judgment:

- a) Requiring ARGYLL, McLAIN and MICELI to account for and to pay over to IMMUNOSYN the short-swing profits realized and retained by them in violation of Section 16(b) of the Act, together with appropriate interest and the costs of this suit;
- b) Awarding to Plaintiff her costs and disbursements including reasonable attorney's, accountants and expert witness fees; and
- c) Granting to Plaintiff such other and further relief as the court may deem just and proper.

Dated: Southampton, New York  
March 6, 2008

Yours, etc.

  
\_\_\_\_\_  
David Lopez, Esq.

**EXHIBIT 3**

Paul D. Wexler (PW 9340)  
BRAGAR WEXLER & EAGEL, P.C.  
885 Third Avenue  
New York, New York 10022  
(212) 308-5858

Glenn F. Ostrager (GO 2023)  
OSTRAGER CHONG FLAHERTY & BROITMAN P.C.  
570 Lexington Avenue  
New York, New York 10022-6894  
(212) 681-0600

Attorneys for Plaintiff

**IN THE UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF NEW YORK**

LEON S. SEGEN, derivatively on behalf of  
IMMUNOSYN CORPORATION,

Plaintiff,

v.

ARGYLL BIOTECHNOLOGIES, LLC,  
CUXHAVEN HOLDINGS LTD.,  
CLAIRSVILLE HOLDINGS, LTD, ARGYLL  
EQUITIES, LLC, DOUGLAS MCCLAIN, JR.,  
JAMES T. MICELI, JOHN DOES 1  
THROUGH 30 and IMMUNOSYN  
CORPORATION,

Defendants.

Civil Action No.

**COMPLAINT**

*(Jury Trial Demanded)*

LEON S. SEGEN ("Segen"), by his attorneys, Bragar Wexler & Eagel, P.C. and Ostrager Chong Flaherty & Broitman P.C., complaining of defendants, alleges upon information and belief as to all paragraphs except paragraph 1, as follows:

1. Plaintiff Segen is a New York resident who is the owner of common stock of Immunosyn Corporation ("Immunosyn" or the "Company").

2. Immunosyn, a nominal defendant herein, is a Delaware corporation with its principal place of business at 4225 Executive Square, Suite 260, La Jolla, California 92037.

3. Defendant Argyll Biotechnologies, LLC ("Argyll Biotechnologies") is a Delaware limited liability company, with its principal place of business at 4225 Executive Square, Suite 260, La Jolla, California 92037. Defendant Douglas McClain, Jr. ("McClain") is the President of Argyll Biotechnologies and defendant James T. Miceli ("Miceli") is the Chief Executive Officer of Argyll Biotechnologies.

4. Defendant Cuxhaven Holdings Ltd. ("Cuxhaven") is a British Virgin Islands company, with its principal place of business at c/o Nunley Davis Jolley Cluck Aelvoet LLP, 1580 South Main Street, Suite 200, Boerne, Texas 78006. Miceli controls and beneficially owns 100% of Cuxhaven.

5. Defendant Clairsvelle Holdings, Ltd. ("Clairsvelle") is a British Virgin Islands company, with its principal place of business at c/o Nunley Davis Jolley Cluck Aelvoet LLP, 1580 South Main Street, Suite 200, Boerne, Texas 78006. McClain controls and beneficially owns 100% of Clairsvelle.

6. Defendant Argyll Equities, LLC ("Argyll Equities") is a Texas limited liability company, with its principal place of business at 4225 Executive Square, Suite 260, La Jolla, California 92037. McClain and Miceli jointly own Argyll Equities. McClain is the President of Argyll Equities, and Miceli is the Chief Executive Officer of Argyll Equities.

7. Defendant McClain is a United States citizen, with a principal place of business at 4225 Executive Square, Suite 260, La Jolla, California 92037. McClain is the President of Argyll Biotechnologies and Argyll Equities. McClain owns 100% of Clairsvelle and also owns 45% of Padmore Holdings, Ltd. ("Padmore"), a holding company established by McClain, McClain's father, and Miceli to hold shares of Immunosyn.

8. Defendant Miceli is a United States citizen, with a principal place of business at 4225 Executive Square, Suite 260, La Jolla, California 92037. Miceli is the Chief Executive Officer of Argyll Biotechnologies and Argyll Equities. Miceli owns 100% of Cuxhaven and also owns 45% of Padmore.

9. John Does 1 through 30 are transferees of Cuxhaven and Clairsvelle, who are identified in Schedule 13D filings made by the named defendants as friends and family members of McClain and Miceli who received and sold shares of Immunosyn. John Does 1 through 10 are deemed to be members of a group with the named defendants, and as such, each of John Does 1 through 30 are greater than 10% beneficial owners of Immunosyn and subject to the short-swing profit recapture provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended.

**Jurisdiction and Venue**

10. This action is brought derivatively on behalf of Immunosyn pursuant to Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C. §78p ("§16(b)"), to obtain disgorgement of profits obtained by defendants in violation of that statute. Jurisdiction of this court and venue in this district are proper pursuant to 15 U.S.C. §78(a)(a).

**The Governing Law**

11. Section 16(b) of the Exchange Act provides that if an officer, director or beneficial owner of more than 10 percent of a class of equity securities of an issuer, purchases and sells or sells and purchases shares of any equity security of such issuer within a period of less than six months, any profits arising from those transactions are recoverable by the issuer or by a shareholder suing derivatively on its behalf.

12. Under SEC Rule 16a-1(a)(1) promulgated under the Exchange Act, where two or more persons "act as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding or disposing of securities of an issuer" as set forth in Section 13(d)(3) of the Exchange Act, such persons are deemed to be a "group" for purposes of determining §16(b) liability. Under SEC Rule 16a-1, the shares held by persons in such a group are aggregated to determine whether the group has a greater than 10% beneficial ownership in the issuing corporation. If the aggregate number of shares beneficially owned by the group exceeds 10%, each member of the group is deemed to be a greater than 10% beneficial owner and is liable to disgorge profits which such group member earned in stock transactions effected within a six-month period.

**CLAIM FOR RELIEF**

13. Defendants Argyll Biotechnologies, Cuxhaven, Clairsvelle, Argyll Equities, McClain, Miceli and John Does 1 through 30 (collectively, the "Argyll Group"), constitute a group under §13(d)(3) of the Exchange Act and garnered short-swing profits disgorgable to Immunosyn in the transactions hereinafter set forth. At all relevant times, Argyll Biotechnologies, McClain and Miceli separately were greater than 10% beneficial owner of

Immunosyn common stock. Additionally, defendant McClain is an Immunosyn statutory insider by virtue of his status as an officer and director of the Company.

**The Purchase Transactions**

14. On August 23, 2007, Argyll Biotechnologies purchased 33,000 shares of Company common stock at a price per share of \$4.55.

15. On August 23, 2007, Argyll Biotechnologies purchased 80,000 shares of Company common stock at a price per share of \$5.00.

16. On June 21, 2007, Argyll Equities purchased 2,700,000 shares of Company common stock at a price per share of \$0.001.

17. On August 24, 2007, Argyll Equities purchased 250,000 shares of Company common stock at a price per share of \$0.001.

**Matchable Sales by Argyll Equities**

18. On April 26, 2007, Argyll Equities sold 1,144,000 shares of Company common stock at a price per share of \$4.55, resulting in disgorgable short-swing profits of \$5,205,000.

19. On April 26, 2007, Argyll Equities sold 37,000 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$185,000.

20. On April 26, 2007, Argyll Equities sold 9,900 shares of Company common stock at a price per share of \$5.05, resulting in disgorgable short-swing profits of \$49,995.

21. On August 23, 2007, Argyll Equities sold 73,000 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$365,000.

22. On October 3, 2007, Argyll Equities sold 37,500 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$187,500.

23. On October 3, 2007, Argyll Equities sold 37,036 shares of Company common stock at a price per share of \$7.50, resulting in disgorgable short-swing profits of \$277,770.

24. On October 18, 2007, Argyll Equities sold 23,500 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$117,500.

25. On October 18, 2007, Argyll Equities sold 249,000 shares of Company common stock at a price per share of \$10.00, resulting in disgorgable short-swing profits of \$2,490,000.

**Matchable Sales by Argyll Biotechnologies**

26. On April 26, 2007, Argyll Biotechnologies sold 77,000 shares of Company common stock at a price per share of \$3.25, resulting in disgorgable short-swing profits of \$250,250.

27. On April 26, 2007, Argyll Biotechnologies sold 166,100 shares of Company common stock at a price per share of \$4.55, resulting in disgorgable short-swing profits of \$755,755.

28. On April 26, 2007, Argyll Biotechnologies sold 124,000 shares of Company common stock at a price per share of \$4.84, resulting in disgorgable short-swing profits of \$600,160.

29. On April 26, 2007, Argyll Biotechnologies sold 45,000 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$225,000.

30. On July 20, 2007, Argyll Biotechnologies sold 127,100 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$635,500.

31. On July 20, 2007, Argyll Biotechnologies sold 4,000 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$20,000.

32. On October 3, 2007, Argyll Biotechnologies sold 375,000 shares of Company common stock at a price per share of \$0.67, resulting in disgorgable short-swing profits of \$251,250.

33. On October 3, 2007, Argyll Biotechnologies sold 25,000 shares of Company common stock at a price per share of \$2.00, resulting in disgorgable short-swing profits of \$50,000.

34. On October 3, 2007, Argyll Biotechnologies sold 119,400 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$597,000.

35. On October 3, 2007, Argyll Biotechnologies sold 140,202 shares of Company common stock at a price per share of \$7.50, resulting in disgorgable short-swing profits of \$1,051,515.

36. On October 18, 2007, Argyll Biotechnologies sold 1,000 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$5,000.

37. On October 18, 2007, Argyll Biotechnologies sold 114,067 shares of Company common stock at a price per share of \$7.50, resulting in disgorgable short-swing profits of \$855,502.50.

38. On October 24, 2007, Argyll Biotechnologies sold 16,000 shares of Company common stock at a price per share of \$5.00, resulting in disgorgable short-swing profits of \$80,000.

39. Each of the matchable sales by Argyll Biotechnologies separately results in disgorgable profits owed by McClain and Miceli in the event that the sales by Argyll Biotechnologies are not matchable with the purchases by Argyll Equities.

40. The August 23, 2007 purchases by Argyll Biotechnologies separately result in disgorgable short-swing profits of \$297,350 when matched with sales by Argyll Biotechnologies on October 3, 2007.

**Sales by John Does 1 through 30**

41. On April 26, 2007, Cuxhaven disposed of 7,290,000 shares of Company common stock to approximately twenty-one (21) personal acquaintances and relatives of Miceli

for no consideration. Each of such persons is believed to have disposed of his or her shares and may be liable for short-swing profits as members of the Argyll Group.

42. On June 21, 2007, Clairsvelle disposed of 760,000 shares of Company common stock to approximately nine (9) personal acquaintances and relatives of McClain for no consideration. Each of such persons is believed to have disposed of his or her shares and may be liable for short-swing profits as members of the Argyll Group.

**As And For A Claim for Relief**

43. Plaintiff repeats and realleges the allegations contained in paragraphs 1 through 42, *supra*, as if fully set forth herein.

44. As itemized in paragraphs 18 through 42, *supra*, defendants are liable for the short-swing profits realized in trading in Immunosyn securities. These transactions yield short-swing profits of approximately \$14,254,897 that defendants must disgorge to Immunosyn pursuant to §16(b).

45. Additional damages may be assessed against defendants as a result of additional purchases and sales of Immunosyn securities of which plaintiff is not aware.

46. Accordingly, plaintiff is entitled to damages on behalf of Immunosyn in an amount which cannot be ascertained with precision at this time, but at least \$14,254,897.

**Allegations As To Demand**

47. On or about October 30, 2007, plaintiff made demand upon Immunosyn to commence this lawsuit. The Company has failed to do so. In a letter dated December 17, 2007,

counsel for Immunosyn advised that the Company had reached a resolution of the claims set forth herein.

**WHEREFORE**, plaintiff demands judgment on behalf of Immunosyn Corporation against defendants, as described above, plus attorneys' fees, interest and such other and further relief as to the Court may seem just and proper.

Dated: New York, New York  
December 19, 2007

Yours, etc.

BRAGAR WEXLER & EAGEL, P.C.

By: Paul D. Wexler  
Paul D. Wexler (PDW9340)

885 Third Avenue  
New York, New York 10022  
(212) 308-5858

OSTRAGER CHONG FLAHERTY  
& BROITMAN P.C.

570 Lexington Avenue  
New York, New York 10022-6894

Attorneys for Plaintiff

## **EXHIBIT 4**

Barry G. Felder  
 Catherine M. McGrath  
 THELEN REID BROWN RAYSMAN & STEINER LLP  
 875 Third Avenue  
 New York, New York 10022  
 (212) 603-2000  
 Attorneys for Defendants Argyll Biotechnologies, LLC, Argyll Equities, LLC,  
 Cuxhaven Holdings, Ltd., Clairsvelle Holdings, Ltd., James T. Miceli  
 and Douglas McClain, Jr.

**UNITED STATES DISTRICT COURT  
 SOUTHERN DISTRICT OF NEW YORK**

---

X

LEON S. SEGEN, derivatively on behalf of	:	
IMMUNOSYN CORPORATION,	:	
	:	
Plaintiff,	:	
	:	Civil Action No. 07-11395 (TPG)
-against-	:	
ARGYLL BIOTECHNOLOGIES, LLC,	:	<b>ANSWER OF DEFENDANTS ARGYLL</b>
CUXHAVEN HOLDINGS, LTD,	:	<b>BIOTECHNOLOGIES, LLC AND</b>
CLAIRSVELLE HOLDINGS, LTD., ARGYLL	:	<b>ARGYLL EQUITIES, LLC TO</b>
EQUITIES, LLC, DOUGLAS MCCLAIN, JR.,	:	<b>PLAINTIFF'S COMPLAINT</b>
JAMES T. MICELI, JOHN DOES 1 THROUGH	:	
30 and IMMUNOSYN CORPORATION,	:	
	:	
Defendants.	:	

---

X

Defendants Argyll Biotechnologies, LLC and Argyll Equities, LLC ("Defendants"), by their attorneys, Thelen Reid Brown Raysman & Steiner LLP, respond to Plaintiff's complaint (the "Complaint") as follows:

1. Defendants deny knowledge or information sufficient to form a belief as to the truth of the allegations in paragraph 1 of the Complaint.
2. Defendants admit the allegations in paragraph 2 of the Complaint.
3. Defendants admit the allegations in paragraph 3 of the Complaint.

4. Defendants deny that James T. Miceli "controls" Cuxhaven Holdings, Ltd., but admit the remainder of the allegations in paragraph 4 of the Complaint.

5. Defendants deny that Douglas McClain, Jr. "controls" Clairsvelle Holdings, Ltd., but admit the remainder of the allegations in paragraph 5 of the Complaint.

6. Defendants admit the allegations in paragraph 6 of the Complaint.

7. Defendants deny that Padmore Holdings, Ltd. was established specifically to hold shares of Immunosyn, but admit the remainder of the allegations in paragraph 7 of the Complaint.

8. Defendants admit the allegations in paragraph 8 of the Complaint.

9. Defendants deny the allegations in paragraph 9 of the Complaint and respectfully refer the Court to Defendants' Schedule 13D filings for their contents and legal implications.

10. Defendants admit that Plaintiff has asserted claims pursuant to 15 U.S.C. § 78p, but deny the remainder of the allegations in paragraph 10 of the Complaint.

11. In response to paragraph 11 of the Complaint, Defendants state that the allegations therein are legal conclusions as to which no response is necessary and, to the extent a response is deemed necessary, Defendants deny the allegations in paragraph 11 and respectfully refer the Court to the cited statute for its contents and legal effect.

12. In response to paragraph 12 of the Complaint, Defendants state that the allegations therein are legal conclusions as to which no response is necessary and, to the extent a response is deemed necessary, Defendants deny the allegations in paragraph 12 and respectfully refer the Court to the cited rule for its contents and legal effect.

13. Defendants deny the allegations in paragraph 13 of the Complaint, except admit that Douglas McClain, Jr. is an officer and director of Immunosyn Corporation and admit that

Douglas McClain, Jr., James T. Miceli and Argyll Biotechnologies, LLC each were and have been the beneficial owners of 10% or more of the common stock of Immunosyn Corporation since its formation.

14. Defendants deny the allegations in paragraph 14 of the Complaint.
15. Defendants deny the allegations in paragraph 15 of the Complaint.
16. Defendants deny the allegations in paragraph 16 of the Complaint.
17. Defendants deny the allegations in paragraph 17 of the Complaint.
18. Defendants deny the allegations in paragraph 18 of the Complaint, except admit that the sale of stock described therein occurred.
19. Defendants deny the allegations in paragraph 19 of the Complaint, except admit that the sale of stock described therein occurred.
20. Defendants deny the allegations in paragraph 20 of the Complaint, except admit that the sale of stock described therein occurred.
21. Defendants deny the allegations in paragraph 21 of the Complaint, except admit that the sale of stock described therein occurred.
22. Defendants deny the allegations in paragraph 22 of the Complaint, except admit that the sale of stock described therein occurred.
23. Defendants deny the allegations in paragraph 23 of the Complaint, except admit that the sale of stock described therein occurred.
24. Defendants deny the allegations in paragraph 24 of the Complaint, except admit that the sale of stock described therein occurred.
25. Defendants deny the allegations in paragraph 25 of the Complaint, except admit that the sale of stock described therein occurred.

26. Defendants deny the allegations in paragraph 26 of the Complaint, except admit that the sale of stock described therein occurred.

27. Defendants deny the allegations in paragraph 27 of the Complaint, except admit that the sale of stock described therein occurred.

28. Defendants deny the allegations in paragraph 28 of the Complaint, except admit that the sale of stock described therein occurred.

29. Defendants deny the allegations in paragraph 29 of the Complaint, except admit that the sale of stock described therein occurred.

30. Defendants deny the allegations in paragraph 30 of the Complaint, except admit that the sale of stock described therein occurred.

31. Defendants deny the allegations in paragraph 31 of the Complaint, except admit that the sale of stock described therein occurred.

32. Defendants deny the allegations in paragraph 32 of the Complaint, except admit that on October 3, 2007, Argyll Biotechnologies, LLC sold 375,000 shares of Immunosyn stock.

33. Defendants deny the allegations in paragraph 33 of the Complaint, except admit that the sale of stock described therein occurred.

34. Defendants deny the allegations in paragraph 34 of the Complaint, except admit that the sale of stock described therein occurred.

35. Defendants deny the allegations in paragraph 35 of the Complaint, except admit that the sale of stock described therein occurred.

36. Defendants deny the allegations in paragraph 36 of the Complaint, except admit that the sale of stock described therein occurred.

37. Defendants deny the allegations in paragraph 37 of the Complaint, except admit that the sale of stock described therein occurred.

38. Defendants deny the allegations in paragraph 38 of the Complaint, except admit that the sale of stock described therein occurred.

39. Defendants deny the allegations in paragraph 39 of the Complaint.

40. Defendants deny the allegations in paragraph 40 of the Complaint.

41. Defendants admit the allegations in paragraph 41 of the Complaint that on April 26, 2007, Cuxhaven Holdings, Ltd. disposed of 7,290,000 shares of common stock in Immunosyn Corporation to approximately 21 personal acquaintances and relatives of James T. Miceli for no consideration, except deny knowledge or information sufficient to form a belief as to the truth of the allegations that “[e]ach of such persons is believed to have disposed of his or her shares,” and deny the remainder of the allegations in paragraph 41 of the Complaint.

42. Defendants admit the allegations in paragraph 42 of the Complaint that on June 21, 2007, Clairsvelle Holdings, Ltd. disposed of 760,000 shares of common stock in Immunosyn Corporation to approximately nine personal acquaintances and relatives of Douglas McClain, Jr. for no consideration, except deny knowledge or information sufficient to form a belief as to the truth of the allegations that “[e]ach of such persons is believed to have disposed of his or her shares,” and deny the remainder of the allegations in paragraph 42 of the Complaint.

43. In response to paragraph 43 of the Complaint, Defendants repeat and reallege the foregoing responses to paragraphs 1 through 42 of the Complaint as if fully set forth herein.

44. Defendants deny the allegations in paragraph 44 of the Complaint.

45. Defendants deny the allegations in paragraph 45 of the Complaint.

46. Defendants deny the allegations in paragraph 46 of the Complaint.

47. Defendants admit the allegations in paragraph 47 of the Complaint.

**FIRST AFFIRMATIVE DEFENSE**

48. Plaintiff fails to state a claim upon which relief may be granted.

**SECOND AFFIRMATIVE DEFENSE**

49. Defendant Argyll Biotechnologies, LLC's August 23, 2007 acquisition of Immunosyn Corporation shares was a transfer for no consideration to correct a clerical error by the transfer agent and was not a "purchase" under Section 16(b) of the Securities Exchange Act.

**THIRD AFFIRMATIVE DEFENSE**

50. Defendant Argyll Equities, LLC's acquisitions of Immunosyn Corporation shares on June 21, 2007 and August 24, 2007 were rescissions or forfeitures of prior transactions and were not "purchases" under Section 16(b) of the Securities Exchange Act.

**THIRD AFFIRMATIVE DEFENSE**

51. The alleged purchases by Argyll Equities, LLC occurred pursuant to agreements entered more than six months prior to any of the alleged sales such that Defendants did not both purchase and sell shares of Immunosyn Corporation within a period of six months.

**FOURTH AFFIRMATIVE DEFENSE**

52. The alleged purchases by defendant Argyll Equities, LLC are exempt from Section 16 liability, if any, pursuant to 240 C.F.R. § 16b-3 because Argyll Equities, LLC, acting as a director-by-deputization of Immunosyn Corporation, acquired its right to obtain the shares at issue and its obligation to pay for them from Immunosyn Corporation.

**FIFTH AFFIRMATIVE DEFENSE**

53. Defendants do not constitute a "group" for purposes of Section 16(b) of the Securities Exchange Act.

**SIXTH AFFIRMATIVE DEFENSE**

54. Each of the alleged purchases by Argyll Equities, LLC was the exercise of an option to repurchase the shares at issue, and therefore the purchase price for purposes of calculating short-swing profits, if any, under Section 16(b) is the market price of the shares at the time of the exercise of the options rather than the exercise price.

WHEREFORE, Defendants demand judgment:

- a. dismissing the Complaint in its entirety; and
- b. awarding to Defendants such other and further relief as the Court deems just and proper.

Dated: April 1, 2008

THELEN REID BROWN RAYSMAN  
& STEINER LLP

By: s/ Barry G. Felder  
Barry G. Felder  
Catherine M. McGrath  
875 Third Avenue  
New York, New York 10022  
(212) 603-2000  
Attorneys for Defendants Argyll Biotechnologies,  
LLC, Argyll Equities, LLC, Cuxhaven Holdings,  
Ltd., Clairsvelle Holdings, Ltd., James T. Miceli  
and Douglas McClain, Jr.

NY #1246961 v1